Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T24982
|
||||
Former ID |
TTDNC00442
|
||||
Target Name |
Ileal bile acid transfer
|
||||
Gene Name |
SLC10A2
|
||||
Synonyms |
ASBT; Apical sodiumdependent bile acid transporter; IBAT; ISBT; Ileal Na(+)/bile acid cotransporter; Ileal sodium/bile acid cotransporter; Ileal sodiumdependent bile acid transporter; Na(+)dependent ileal bile acid transporter; Sodium/taurocholate cotransporting polypeptide, ileal; Solute carrier family 10 member 2; SLC10A2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10: E78] | ||||
Lipid metabolism disorder [ICD10: E75-E78] | |||||
Primary biliary cirrhosis [ICD9: 571.6; ICD10: K74.3] | |||||
Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
Unspecified [ICD code not available] | |||||
Function |
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
|
||||
BioChemical Class |
Bile acid:na(+) symporter
|
||||
UniProt ID | |||||
Sequence |
MNDPNSCVDNATVCSGASCVVPESNFNNILSVVLSTVLTILLALVMFSMGCNVEIKKFLG
HIKRPWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVD GDMDLSVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVSLVVPVSIGM FVNHKWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWIIAPKLWIIGTIFPVAGYSL GFLLARIAGLPWYRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVFTFPLIYSIFQLAF AAIFLGFYVAYKKCHGKNKAEIPESKENGTEPESSFYKANGGFQPDEK |
||||
Drugs and Mode of Action | |||||
Drug(s) | A-3309 | Drug Info | Phase 3 | Lipid metabolism disorder | [524353] |
264W94 | Drug Info | Phase 2 | Hyperlipidaemia | [531629], [541657] | |
GSK2330672 | Drug Info | Phase 2 | Type 2 diabetes | [532355] | |
LUM001 | Drug Info | Phase 2 | Primary biliary cirrhosis | [525031] | |
S-8921 | Drug Info | Phase 2 | Hyperlipidaemia | [534690] | |
1614235 + 2330672 | Drug Info | Phase 1 | Type 2 diabetes | [549464] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Bile secretion | ||||
Reactome | Recycling of bile acids and salts | ||||
WikiPathways | Bile acid and bile salt metabolism | ||||
References | |||||
Ref 524353 | ClinicalTrials.gov (NCT01895543) Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation. U.S. National Institutes of Health. | ||||
Ref 525031 | ClinicalTrials.gov (NCT02321306) An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis. U.S. National Institutes of Health. | ||||
Ref 531629 | Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. | ||||
Ref 532355 | Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. | ||||
Ref 534690 | Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11. | ||||
Ref 531629 | Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. | ||||
Ref 532143 | Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. | ||||
Ref 532355 | Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. | ||||
Ref 534551 | Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. | ||||
Ref 534690 | Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.